Elpro to Acquire Cohance Lifesciences for INR 47.9 million
Verified article - details checked for accuracy.
Elpro International Ltd is buying Cohance Lifesciences Ltd for INR 47.9 million—a tiny slice of Cohance’s INR 11.98 billion turnover—aiming to add CDMO capabilities and a U.S. foothold.
- Deal basics: Cash payment of INR 47.9 million; arms‑length, non‑related‑party transaction; post‑deal ownership not disclosed (Cohance had 0 % Elpro share before).
- Cohance’s size: FY 2024‑25 turnover INR 11.98 billion, PAT INR 2.65 billion, net worth INR 16.97 billion, operating in India and the United States.
- Strategic upside: Provides Elpro with CDMO, API, specialty‑chemical, and formulation services; opens a high‑margin U.S. market; creates cross‑selling opportunities with existing clients.
- Investor view: Low cash outlay limits immediate strain, but execution risk (integration, possible need for extra capital) remains; potential for stronger revenue streams and market positioning.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.